Tianjin Zhong Xin Pharmaceutical Group Corporation Limited operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Tianjin Zhong Xin Pharmaceutical Group Corporation Limited with three other
companies in this sector in China:
Northeast Pharmaceutical Group Co., Ltd.
sales of 5.68 billion Chinese Renmimbi [US$827.21 million]
of which 64%
was Pharmaceutical Products),
Hubei Jumpcan Pharmaceutical Co Ltd
(5.64 billion Chinese Renmimbi [US$822.21 million]
of which 96%
was Industrial), and
Zhejiang Medicine Co., Ltd.
(5.69 billion Chinese Renmimbi [US$829.58 million]
of which 43%
was Life Nourishment).
During the year ended December of 2017, sales at
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited were 5.69 billion Chinese Renmimbi (US$829.09 million).
decrease of 7.9%
versus 2016, when the company's sales were 6.18 billion Chinese Renmimbi.
Contributing to the drop in overall sales was the 10.3% decline
in Chinese Medicine, from 4.07 billion Chinese Renmimbi to 3.65 billion Chinese Renmimbi.
There were also decreases in sales in
Western Medicine (down 9.1% to 1.49 billion Chinese Renmimbi)
However, these declines were partially offset by the increase in sales of
Others (up 16.5% to 549.48 million Chinese Renmimbi)